Compare Medicare Part D Plans

Compare the company portfolio first, then the exact Part D plan

This comparison is designed to help you narrow Medicare Part D companies before you move into the exact regional plan details that determine what you would actually pay. That distinction matters because a standalone Part D company can market one or several plan families nationally while premiums, deductibles, formularies, drug tiers, preferred pharmacies and cost sharing can vary by CMS PDP region and by the specific plan benefit package available where you live.

The side-by-side table therefore focuses on facts that make sense at the portfolio level: the 2026 plan year, marketed plan families, portfolio scope, company structure, CMS Part D Star Rating context and MarketReview editorial findings. It does not turn one regional specimen into a national premium or deductible. That would make the table look more precise while making the comparison less accurate.

Use the table to answer a narrower first question: which two or three companies deserve detailed prescription-level checking? A company with several plan families may give you more internal choices. Another may offer one primary PDP family and a simpler decision path. Portfolio structure can help narrow the field, but it cannot prove that one company's exact plan will be the lowest-cost option for your prescriptions.

Once you have a shortlist, move to the exact plans offered in your ZIP code or PDP region. Enter every prescription you take, compare the formulary status and tier for each drug, check utilization-management rules, and price the drugs at pharmacies you are willing to use. The company-level comparison should reduce the field. The exact-plan comparison should make the enrollment decision.

A formulary mismatch can outweigh a lower monthly premium

Monthly premium is one of the most visible Part D numbers, but it should not be the first number you optimize. The more important starting point is whether the exact plan covers the medications you expect to use and how it places them on its formulary. A plan with a lower premium can become the more expensive choice if one of your prescriptions is placed on a costly tier, subject to percentage coinsurance, or not covered in the way you expected.

Part D plans must follow Medicare coverage rules and cover a broad range of prescription drugs, but formularies are still plan-specific. Plans can organize covered drugs into tiers with different cost sharing. They can also use prior authorization, step therapy and quantity limits. Medicare describes all three as common plan rules. Prior authorization can require approval before coverage applies, step therapy can require trying another drug first, and quantity limits can restrict how much the plan covers over a given period.

That is why the comparison table does not claim that one portfolio has the best formulary for everyone. A company can look strong at the portfolio level while one exact regional plan is a poor fit for a particular medication list. The reverse can also be true. A company that does not stand out on broad marketing claims may offer an exact plan that handles your prescriptions unusually well.

For routine generics, compare the tier, copay and deductible treatment rather than assuming all low-cost drugs behave alike. For expensive brand or specialty drugs, pay even closer attention to coinsurance and restrictions. If a medication has been difficult to cover before, verify its exact formulary entry and any utilization-management notation before you enroll. The best company-level shortlist is the one that gets you efficiently to that drug-by-drug check.

Compare total prescription cost, not one headline number

Part D cost has several moving parts. You may pay a monthly premium, a deductible, copays or coinsurance when prescriptions are filled, and an income-related adjustment if your income is above the applicable threshold. The exact mix depends on the plan and your situation. A company comparison is useful for understanding portfolio design, but total annual cost becomes personal only after your drugs and pharmacies are added.

For 2026, Medicare's defined standard Part D benefit has a maximum deductible of $615 and an annual out-of-pocket threshold of $2,100 for covered Part D drugs. Plans can use a lower deductible, including a $0 deductible, and their tier-level cost sharing can differ from the standard design within Medicare rules. Once an enrollee reaches the 2026 out-of-pocket threshold for covered Part D drugs, the enrollee pays no cost sharing for covered Part D drugs in the catastrophic phase.

Those common federal parameters are useful, but they do not eliminate the need to compare plans. One plan may charge a deductible only on certain tiers. Another may use a different pattern of copays and coinsurance. Preferred-pharmacy pricing can change the cost again. A lower premium may save money for someone with few prescriptions while doing little for a person whose annual spending is driven by expensive brand drugs.

When you move from this page to exact plan pricing, compare the full-year estimate rather than sorting only by premium. Look at what happens before and after the deductible, how often each prescription is filled, whether a 90-day supply changes the cost, and what you would pay at your actual pharmacy. If two plans have similar annual estimates, then premium stability, plan-family design, pharmacy convenience and service can become more meaningful tie-breakers.

Preferred pharmacies can change the result without changing the drug

A pharmacy being in network does not always mean it produces the lowest available plan price. Many Part D plans distinguish between preferred in-network pharmacies and standard in-network pharmacies. The preferred category can carry lower cost sharing for some prescriptions because the pharmacy and plan have different pricing arrangements. This can make the pharmacy column of your research just as important as the premium column.

Suppose two plans both cover the same drug on the same tier. If your regular pharmacy is preferred under one plan but standard under the other, the annual difference can be meaningful even though the formulary comparison initially looks identical. If you are willing to change pharmacies, the plan with a stronger preferred-pharmacy arrangement in your area may become more attractive. If you rely on one independent pharmacy or a specific chain, that flexibility may not exist.

Carrier materials also change over time, and pharmacy networks can be updated. Current plan documents and pharmacy directories are therefore more useful than a general statement that a company has a broad network. Some portfolios may offer extensive national access, but the practical question is whether the pharmacies you can realistically use are in network and whether they have preferred cost-sharing status under the exact plan.

Use this company comparison to identify portfolios worth investigating, then price the same prescription list at more than one convenient pharmacy when possible. A plan that appears expensive at one pharmacy can look different at another. This is especially worth checking for people who fill several recurring prescriptions, live near multiple major chains, or split time between locations during the year.

More plan families create more choice, but also more ways to compare the wrong plans

The 2026 standalone Part D portfolios in this comparison do not all have the same shape. Some companies market several PDP families with different positioning, while another may concentrate its offering in one main family. That difference is worth showing because it changes the research task before you even reach the exact regional benefit details.

Humana currently markets three 2026 standalone PDP families. Wellcare and HealthSpring each market multiple standalone families, while Aetna Medicare's SilverScript offering is centered on SilverScript Choice. The AARP/UnitedHealthcare standalone portfolio also gives shoppers more than one family to investigate. These family names are useful orientation points, not proof that the same pricing or benefit design applies nationally.

A multi-family portfolio can be helpful when the company's options are meaningfully differentiated. One family may emphasize lower premium, another a broader or richer benefit structure, and another may be positioned for people receiving Extra Help. The risk is that shoppers compare a low-premium family from one company against a richer family from another and treat the result as a carrier comparison. In reality, they may be comparing two different benefit strategies.

A single-family portfolio is not automatically limited, and a larger family count is not automatically better. What matters is whether at least one exact plan available to you handles your prescriptions and pharmacies at an acceptable total cost. Use the Plan families row in the table to understand how much internal choice each company presents. Then compare like with like when you reach exact plan documents.

Thirty-day and 90-day fills can change which plan looks cheaper

The way you refill a prescription can materially change a Part D cost comparison. A plan may price a 30-day retail fill one way and a 90-day supply another way, and the result can differ again between a preferred retail pharmacy and mail order. That means a shopper who routinely fills maintenance medications for three months at a time may see a different annual winner than someone comparing only 30-day pharmacy prices.

This matters most for stable medications you expect to take throughout the year. If two exact plans cover the same drug on the same tier, compare the cost of the refill pattern you would actually use. A lower 30-day copay does not automatically mean the plan remains cheaper over twelve months. Conversely, a plan that advertises attractive extended-supply pricing may not be the better fit if you rarely use 90-day fills or if your preferred pharmacy does not receive the most favorable cost sharing.

Mail order should be tested the same way rather than treated as an automatic savings feature. Some people value delivery and fewer refill trips, while others need the flexibility of a local pharmacy because prescriptions change or must be started quickly. For maintenance drugs, compare 30-day retail, 90-day retail and mail-order pricing when those options are available under the exact plan. For short-term or frequently adjusted medications, convenience and flexibility may matter more than an extended-supply discount.

The company-level table cannot settle this question because refill pricing belongs to the exact regional plan. What it can do is narrow the portfolios worth checking. Once you reach plan-specific tools, recreate the comparison using the quantity and refill frequency you actually expect to use. That produces a more realistic annual estimate than comparing a single default fill.

Extra Help can change the value of the same Part D portfolio

Medicare Extra Help changes how many beneficiaries experience Part D costs, so a portfolio that looks ordinary for a full-premium shopper may be more relevant for someone receiving the low-income subsidy. Extra Help can reduce prescription costs and may reduce the premium a beneficiary pays for qualifying plans. People who receive Extra Help also do not pay the Part D late enrollment penalty.

Several 2026 carriers explicitly position certain plan families for beneficiaries receiving Extra Help. Wellcare describes Classic as a plan where eligible Extra Help members may qualify for a $0 premium and lower copays. Humana describes Basic Rx as an option designed with Extra Help beneficiaries in mind, subject to the applicable benchmark and location. Aetna states that SilverScript Choice may lower premiums for people who qualify for Extra Help. Those statements are reasons to investigate the exact subsidy interaction, not promises that every eligible person will pay the same amount everywhere.

If you receive Extra Help, do not compare companies using the ordinary retail premium alone. Check the exact plan's low-income premium information, the LIS rider, your prescription cost sharing and the formulary. The benchmark relationship can vary geographically, and your subsidy level affects what you actually pay. A portfolio that looks expensive before subsidy information is applied may look different after it is applied correctly.

If you do not currently receive Extra Help but think you may qualify, confirm eligibility before treating standard plan pricing as your final cost. This page can still help you narrow companies, but the exact plan and subsidy calculations should drive the final comparison.

The Medicare Prescription Payment Plan changes timing, not total drug cost

All Medicare drug plans offer the Medicare Prescription Payment Plan, which can spread eligible out-of-pocket prescription costs across the remaining months of the calendar year. This can be useful for people who face high covered drug costs early in the year and prefer not to pay the entire amount at the pharmacy when the prescription is filled.

The important comparison point is what the program does not do. Medicare states that the payment option does not save money or lower drug costs. It changes when you pay. You continue to owe your plan premium separately, and the amount billed under the payment plan can change as new prescription costs are added during the year. The same $2,100 annual out-of-pocket maximum for covered Part D drugs in 2026 applies whether or not you participate.

Because every Part D sponsor must offer the option, its existence is not a meaningful way to rank the companies in this table. The better question is whether a carrier provides understandable enrollment and account-management tools if you decide to use it. That can matter for usability, but it comes after formulary fit and total prescription cost.

If smoothing payments is important to you, estimate the exact plan's annual drug costs first. A plan with lower total cost is generally more valuable than a more expensive plan whose costs are simply easier to spread over the year. Once the underlying cost comparison works, the payment option can help with cash-flow management.

Digital tools and service matter most after coverage fit is established

Part D is not a set-it-and-forget-it product for everyone. During the year you may need to check a drug price, find a network pharmacy, review an Explanation of Benefits, request a coverage determination, track an appeal or understand why a claim processed differently from what you expected. Those moments make a carrier's member tools and service processes more important than they appear during initial shopping.

Current carrier resources show different ways of handling those tasks. Aetna Medicare directs standalone PDP members to CVS Caremark tools for prescription pricing, pharmacy search, refills and mail-order delivery. HealthSpring publishes plan-specific 2026 formularies, prior-authorization criteria, step-therapy criteria and pharmacy directories for its standalone PDP families. Wellcare also maintains plan-specific documents, formularies and pharmacy information. Other carriers provide their own drug-search, pharmacy and account-management paths.

The existence of an online tool should not carry the same weight as drug coverage or annual cost. A polished website cannot make an uncovered prescription affordable. Still, when two exact plans both handle your medications well and produce similar annual estimates, ease of use becomes a legitimate secondary consideration. It can reduce friction when a prescription changes or when you need to verify a pharmacy before filling a drug.

When you read the individual reviews, look for specific service infrastructure rather than vague claims about convenience. Can you price a medication without calling? Can you find current formulary documents? Is the pharmacy directory easy to reach? Are coverage-determination and appeal resources clearly available? Those details help turn a company-level comparison into a more realistic picture of what using the plan may require.

The final comparison happens with your ZIP code, prescriptions and pharmacies

A useful Part D company comparison should make the next step smaller, not pretend the next step is unnecessary. After you select two or three portfolios here, use current plan-search tools to identify the exact 2026 standalone PDPs available where you live. Then recreate the comparison using your real prescription list and the pharmacies you are willing to use.

Confirm the exact monthly premium, deductible, drug tier, copay or coinsurance, preferred-pharmacy status and utilization-management rules. If you use mail order, check that cost separately rather than assuming it is always cheaper. If you take an expensive drug, review the formulary entry and any prior authorization, step therapy or quantity-limit notation. If you receive Extra Help, use the subsidy-specific plan information rather than ordinary cost sharing.

Also check whether your current plan changed for the new year. Formularies, premiums, cost sharing and pharmacy arrangements can change from one plan year to the next. A company that worked well last year may still be a good fit, but automatic renewal is not the same thing as a fresh comparison. Part D is especially sensitive to changes in the medications you take.

If a prescription is newly added, discontinued, switched to a different dose or moved to a different pharmacy, rerun the comparison rather than relying on the estimate you made earlier in the year. Even a small change in the medication list can alter which exact plan is the better financial fit, especially when one drug carries coinsurance or a utilization rule.

The strongest use of this page is therefore selective. Compare portfolio structure and editorial context here, read a full review when one company remains interesting, then let exact plan data settle the financial question. If no company clearly stands out at the portfolio level, that is not a problem. The plan with the best combination of covered drugs, pharmacy access and annual cost for you can still emerge once the exact regional options are priced.